tradingkey.logo

ENDRA Life Sciences Inc

NDRA
5.100USD
0.000
收盘 12/24, 13:00美东报价延迟15分钟
4.01M总市值
0.00市盈率 TTM

ENDRA Life Sciences Inc

5.100
0.000

关于 ENDRA Life Sciences Inc 公司

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.

ENDRA Life Sciences Inc简介

公司代码NDRA
公司名称ENDRA Life Sciences Inc
上市日期Jun 28, 2017
CEOTokman (Alexander Y)
员工数量21
证券类型Ordinary Share
年结日Jun 28
公司地址3600 Green Ct Ste 350
城市ANN ARBOR
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编48105
电话17343350468
网址https://www.endrainc.com/
公司代码NDRA
上市日期Jun 28, 2017
CEOTokman (Alexander Y)

ENDRA Life Sciences Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.81K
+1200.99%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
--
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-99.96%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Anthony DiGiandomenico
Mr. Anthony DiGiandomenico
Independent Director
Independent Director
70.81K
+1200.99%
Mr. Alexander Y. Tokman
Mr. Alexander Y. Tokman
Chairman of the Board, Acting Chief Executive Officer
Chairman of the Board, Acting Chief Executive Officer
5.00
--
Mr. Michael Harsh
Mr. Michael Harsh
Independent Director
Independent Director
2.00
-99.96%
Mr. Louis J. Basenese
Mr. Louis J. Basenese
Independent Director
Independent Director
--
--
Ms. Yvonne Briggs
Ms. Yvonne Briggs
Investor Relations
Investor Relations
--
--
Mr. Richard Jacroux
Mr. Richard Jacroux
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月22日 周六
更新时间: 11月22日 周六
持股股东
股东类型
持股股东
持股股东
占比
ATW Partners LLC
9.95%
Lipman (John Carter)
6.52%
DiGiandomenico (Anthony)
6.07%
DRW Securities, LLC
1.09%
Geode Capital Management, L.L.C.
0.44%
其他
75.93%
持股股东
持股股东
占比
ATW Partners LLC
9.95%
Lipman (John Carter)
6.52%
DiGiandomenico (Anthony)
6.07%
DRW Securities, LLC
1.09%
Geode Capital Management, L.L.C.
0.44%
其他
75.93%
股东类型
持股股东
占比
Individual Investor
12.60%
Private Equity
9.95%
Investment Advisor
1.34%
Investment Advisor/Hedge Fund
0.44%
Hedge Fund
0.02%
其他
75.66%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
24
12.65K
1.08%
+1.88K
2025Q2
34
22.09K
2.99%
+12.79K
2025Q1
37
5.94K
0.98%
+652.00
2024Q4
38
889.00
0.17%
-4.90K
2024Q3
39
6.39K
8.81%
+5.79K
2024Q2
39
2.03K
9.18%
+1.72K
2024Q1
33
352.00
9.94%
+101.00
2023Q4
35
276.00
9.44%
+68.00
2023Q3
37
286.00
9.99%
+78.00
2023Q2
39
314.00
10.85%
+151.00
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
DiGiandomenico (Anthony)
5.44K
0.72%
+5.38K
+9125.42%
Jun 11, 2025
Geode Capital Management, L.L.C.
5.13K
0.68%
+594.00
+13.09%
Aug 31, 2025
The Vanguard Group, Inc.
116.00
0.02%
--
--
Aug 31, 2025
UBS Financial Services, Inc.
4.70K
0.62%
+4.70K
--
Jun 30, 2025
Northwestern Mutual Capital, LLC
35.00
0%
+35.00
--
Jun 30, 2025
Thornton (Michael Milos)
20.00
0%
--
--
Mar 24, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
公告日期
类型
比率
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Nov 05, 2024
Merger
35→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Aug 16, 2024
Merger
50→1
Dec 06, 2022
Merger
20→1
Dec 06, 2022
Merger
20→1
查看更多

常见问题

ENDRA Life Sciences Inc的前五大股东是谁?

ENDRA Life Sciences Inc 的前五大股东如下:
DiGiandomenico (Anthony)持有股份:5.44K,占总股份比例:0.72%。
Geode Capital Management, L.L.C.持有股份:5.13K,占总股份比例:0.68%。
The Vanguard Group, Inc.持有股份:116.00,占总股份比例:0.02%。
UBS Financial Services, Inc.持有股份:4.70K,占总股份比例:0.62%。
Northwestern Mutual Capital, LLC持有股份:35.00,占总股份比例:0.00%。

ENDRA Life Sciences Inc的前三大股东类型是什么?

ENDRA Life Sciences Inc 的前三大股东类型分别是:
ATW Partners LLC
Lipman (John Carter)
DiGiandomenico (Anthony)

有多少机构持有ENDRA Life Sciences Inc(NDRA)的股份?

截至2025Q3,共有24家机构持有ENDRA Life Sciences Inc的股份,合计持有的股份价值约为12.65K,占公司总股份的1.08%。与2025Q2相比,机构持股有所增加,增幅为-1.91%。

哪个业务部门对ENDRA Life Sciences Inc的收入贡献最大?

在--,--业务部门对ENDRA Life Sciences Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI